Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avalyn PharmaAVLN -1.01%11 Current Ratio is 10.19 as of Dec. 2025, which is 12% below its 10-year median of 11.64. GuruFocus rates AVLN with a GF Score™ of 11/100. Among 1,411 Biotechnology companies, Avalyn Pharma ranks better than 78.53% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Avalyn Pharma's current ratio for the quarter that ended in Dec. 2025 was 10.19.
Avalyn Pharma has a current ratio of 10.19. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Avalyn Pharma's Current Ratio or its related term are showing as below:
AVLN'
s Current Ratio Range Over the Past 10 Years
Min: 10.19 Med: 11.64 Max: 13.08
Current: 10.19
During the past 2 years, Avalyn Pharma's highest Current Ratio was 13.08. The lowest was 10.19. And the median was 11.64.
AVLN's Current Ratio is ranked better than 78.53% of 1411
companies
in the Biotechnology industry
Industry Median: 3.85
vs AVLN: 10.19
Avalyn Pharma (NAS:AVLN) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Avalyn Pharma Current Ratio Related Terms
Avalyn Pharma Current Ratio Historical Data
* Premium members only.
The historical data trend for Avalyn Pharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalyn Pharma Current Ratio Chart
Avalyn Pharma Annual Data
Trend
Dec24
Dec25
Current Ratio
13.08
10.19
Avalyn Pharma Semi-Annual Data
Dec24
Dec25
Current Ratio
13.08
10.19
AVLN vs TRAX, IMTX, ARDX: Current Ratio Comparison
For the Biotechnology subindustry, Avalyn Pharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avalyn Pharma Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avalyn Pharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where Avalyn Pharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalyn Pharma (AVLN) has a Current Ratio of 10.19 as of Dec. 2025. This is 12% below median its historical median of 11.64. Over the past decade, Avalyn Pharma's Current Ratio has ranged from 10.19 to 13.08. According to the industry distribution chart, Avalyn Pharma ranks #303 out of 1411 companies in the Biotechnology industry, placing it in the top 21.5%.
Is Avalyn Pharma's Current Ratio too high?
Avalyn Pharma's current Current Ratio of 10.19 is 12% below median its 10-year median of 11.64. Over the past 10 years, this metric has ranged from a low of 10.19 to a high of 13.08. The Biotechnology industry median Current Ratio is 3.85. Avalyn Pharma's value of 10.19 is 164.7% above this industry median. Based on the distribution chart, Avalyn Pharma ranks #303 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Avalyn Pharma has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Avalyn Pharma's Current Ratio compare to TRAX and IMTX?
According to the Biotechnology industry distribution chart, Avalyn Pharma ranks #303 out of 1411 companies for Current Ratio. This places Avalyn Pharma in the top 22% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.85. Avalyn Pharma's value of 10.19 is 164.7% above this benchmark. Historically, Avalyn Pharma's own Current Ratio has ranged from 10.19 to 13.08 over the past decade. While the company's 10-year median is 11.64 vs. the industry median of 3.85, Avalyn Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.85, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avalyn Pharma's current Current Ratio of 10.19 is 164.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avalyn Pharma's current Current Ratio is 10.19, which is 12% below median its own 10-year median of 11.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avalyn Pharma stock overvalued right now?
Avalyn Pharma (AVLN) has a current Current Ratio of 10.19. The current Current Ratio is 10.19, which is 12% below median its 10-year median of 11.64 and 164.7% above the Biotechnology industry median of 3.85. Avalyn Pharma's overall GF Score™ is 11/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Avalyn Pharma (AVLN), the current Current Ratio is 10.19 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
11GF Score
Get the complete analysis for AVLN
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVLN has been successfully added to your 
